VIVUS (VVUS) Hits New 52-Week Low at $0.51
Shares of VIVUS, Inc. (NASDAQ:VVUS) hit a new 52-week low during trading on Monday . The stock traded as low as $0.51 and last traded at $0.53, with a volume of 679100 shares trading hands. The stock had previously closed at $0.55.
Separately, ValuEngine upgraded VIVUS from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd.
The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86. The company has a market cap of $56.43, a P/E ratio of 1.57 and a beta of 0.77.
VIVUS (NASDAQ:VVUS) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.07. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The business had revenue of $15.19 million for the quarter, compared to the consensus estimate of $16.00 million. During the same period last year, the business posted ($0.09) EPS. The company’s revenue was up 13.8% compared to the same quarter last year. sell-side analysts expect that VIVUS, Inc. will post -0.32 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the business. AJO LP purchased a new stake in VIVUS during the 2nd quarter valued at $3,329,000. OxFORD Asset Management LLP boosted its stake in shares of VIVUS by 58.2% in the 2nd quarter. OxFORD Asset Management LLP now owns 929,511 shares of the biopharmaceutical company’s stock worth $1,134,000 after buying an additional 341,976 shares during the last quarter. IHT Wealth Management LLC boosted its stake in shares of VIVUS by 653.3% in the 2nd quarter. IHT Wealth Management LLC now owns 1,130 shares of the biopharmaceutical company’s stock worth $1,100,000 after buying an additional 980 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of VIVUS by 7.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,564 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 7,722 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of VIVUS by 84.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 68,200 shares during the last quarter. Institutional investors and hedge funds own 31.35% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/12/18/vivus-vvus-hits-new-52-week-low-at-0-51.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.